key: cord-0851158-mhy0ptc3 authors: Liu, Yang; He, Huanzhong; Huang, Huilian title: The role and significance of angiotensin‐converting enzyme 2 peptides in the treatment of coronavirus disease 2019 date: 2021-05-05 journal: J Clin Lab Anal DOI: 10.1002/jcla.23789 sha: 7f11d42e0f9291eed876f0ac7f091bc44777ea58 doc_id: 851158 cord_uid: mhy0ptc3 Since the end of 2019, coronavirus disease 2019 (COVID‐19) caused by the novel coronavirus (2019‐nCoV) posed a serious threat to human health and life. Therefore, the discovery of drugs that can effectively prevent and treat COVID‐19 is urgently warranted. In this article, the role and significance of angiotensin‐converting enzyme 2 in drug development and the treatment of COVID‐19 are discussed. It was found that the binding of ACE2 to SARS‐CoV‐2‐RBD involved two core regions (31st and 353rd lysine) and 20 amino acids of the ACE2 protein. The mutation of these amino acids could lead to a great change of the binding ability of ACE2 and SARS‐CoV‐2‐RBD. This information was important for us to find more efficient ACE2 peptides to block the 2019‐nCoV infection. So during this study, we summarized the role of ACE2 in the regulation of 2019‐nCoV infection and stress, and hypothesized that the development and optimization of ACE2 peptide can effectively block 2019‐nCoV infection and reliably treat the COVID‐19. an effective and specific pharmacological agent for the treatment of COVID-19. Hence, the battle against SARS-CoV-2 remains at the stage of continuous exploration. Since the outbreak of SARS-CoV-2, scientists have carried out intensive research to establish a more comprehensive scientific basis for the treatment of COVID-19. Similar to the pathogenic mechanism of SARS-CoV, SARS-CoV-2 also attaches to the host cell through binding of the receptor binding domain (RBD) in the S1 subunit of S (Spike) protein to the cellular receptor ACE2 and enters the cells via endocytosis. [8] [9] [10] [11] This leads to progression and deterioration of the disease. SARS-CoV-2 can easily invade the human body through the combination of RBD and ACE2. Researchers determined the structure of the SARS-CoV-2 spike protein using cryo-electron microscopy, and found that the SARS-CoV-2 spike protein exhibits significantly higher ACE2-binding affinity than the SARS-CoV spike protein (10-20-fold higher). 12 This fully explains the markedly more efficient transmission of SARS-CoV-2 versus SARS-CoV, and also reveals the important role of ACE2 in the process of SARS-CoV-2 infection. Therefore, using ACE2 receptor protein as a target, we may be able to discover a specific drug for the treatment of COVID-19. ACE2 is a multifunctional type I transmembrane glycoprotein with a single extracellular catalytic domain. 13 It belongs to the ACE family and is the homolog of ACE. ACE and ACE2 are involved in the regulation of the renin-angiotensin system (RAS). The ACE/angiotensin II/angiotensin II type 1 receptor (ACE/Ang II/AT1R) axis regulates signaling pathways to increase blood pressure and promote inflammatory reactions. The signaling pathway regulated by the ACE2/Ang1-7/MAS axis has been associated with vasodilatory, anti-oxidative, and anti-inflammatory effects. [14] [15] [16] A previous study demonstrated that SARS-CoV-2 infections caused a downregulation of ACE2 expression. [17] [18] [19] This led to imbalance in the RAS system, promotion of inflammation, and further disease progression. In some patients with cardiovascular disease, diabetes, etc., SARS-CoV-2 infection is accelerated by overexpression of ACE2. 20, 21 Consequently, elderly individuals accounted for 80% of the clinical deaths caused by SARS-CoV-2, and 75% of those patients suffered from cardiovascular disease, diabetes, and other underlying diseases. Using single-cell analysis technology, researchers found that ACE2 is abundantly expressed in human alveolar type II epithelial cells and colonic epithelial cells. Furthermore, gene functional enrichment analysis revealed the genes that are relevant to viral infections in human alveolar type II epithelial cells and colonic epithelial cells with high expression of ACE2. These mainly include genes regulating virus invasion and release, recognizing virus nucleic acid and type I/ III interferon signaling, pro-inflammatory cytokines and chemokines, the major histocompatibility complex I (MHC I) antigen presentation pathway, and cytokine receptors. 22, 23 The results of that study indicated that entry of the virus into cells through ACE2 leads to undetermined consequences. It has been found that the new small-molecule peptides prepared from the N-terminal 21-43 amino acid protein of ACE2 can effectively bind to SARS-CoV-2-RBD. 26 However, recent studies using the deep parsing approach for the structural investigation of SARS-CoV-2 and ACE2 binding showed that the binding of ACE2 to SARS-CoV-2-RBD involves two core regions (31st and 353rd lysine) of the ACE2 protein. 27, 28 Whether the new small-molecule peptides pre- analyzed the data and wrote the manuscript. The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0001-9800-7670 Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19 China novel coronavirus investigating and research team. A novel coronavirus from patients with pneumonia in China Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: a multicenter descriptive study A comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia Clinical features of patients infected with 2019 novel coronavirus in Wuhan A novel coronavirus outbreak of global health concern Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody A pneumonia outbreak associated with a new coronavirus of probable bat origin Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decadelong structural studies of SARS coronavirus Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation The ACE2/ Angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin Recombinant human ACE2 and the angiotensin 1-7 axis as potential new therapies for heart failure 2 Schematic diagram of small-molecule soluble ACE2 peptides used in the treatment of COVID-19. ACE2, angiotensinconverting enzyme 2 Role of the ACE2/ Angiotensin 1-7 axis of the renin-angiotensin system in heart failure ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the reninangiotensin system: celebrating the 20th anniversary of the discovery of ACE2 Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig The first-in-class peptide binder to the SARS-CoV-2 spike protein Structural basis of receptor recognition by SARS-CoV-2 Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor